cancer biology – Page 5 – Retraction Watch

SAGE journal retracts three more papers after discovering faked reviews

SAGE recently retracted three 2015 papers from one of its journals after the publisher found the articles were accepted with faked peer reviews. The retraction notices call out the authors responsible for submitting the reviews.

This trio of retractions is the second batch of papers withdrawn by Technology in Cancer Research & Treatment over faked reviews in the past eight months. In 2016, the journal began investigating concerns from an anonymous tipster about faked reviewer reports and subsequently retracted three papers in December over “manipulation of the peer-review process” (1, 2, 3).

Jennifer Lovick, the journal’s executive editor, told us the recent issues have prompted the journal to take steps to strengthen the peer review process: Continue reading SAGE journal retracts three more papers after discovering faked reviews

“The article must be retracted:” Journal pulls prostate cancer study

A 2016 paper exploring the biology of prostate cancer has been retracted due to figure manipulation.

According to the retraction notice, a reader contacted the journal Clinical Cancer Research in late 2016 with concerns that similar bands appeared multiple times in two images. The editors asked the paper’s corresponding author, Shahriar Koochekpour, about the issue and requested the raw data for the figures. But Koochekpour, based in the Departments of Cancer Genetics and Urology at Roswell Park Cancer Institute in Buffalo, New York, at the time of the study, could not locate the raw data.

Since the lab did not have raw data from such a relatively recent paper, the editors reached out to the research integrity officer at Roswell Park Cancer Institute to investigate. Indeed, the research integrity officer contacted confirmed that two figures were problematic, and requested the paper be retracted.

Here’s the rather detailed retraction notice, published in July 2017, for “GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models:” Continue reading “The article must be retracted:” Journal pulls prostate cancer study

“We do not want to create false hope”: Authors retract Cell paper they can’t replicate

A few years ago, researchers in Sweden had something to celebrate: They thought they had discovered a chink in the armor of the most common type of malignant brain cancer.

In a 2014 Cell paper, the team — led by Patrik Ernfors at the Karolinska Institutet — reported that they had identified a small molecule that could target and kill glioblastoma cells — the cancer that U.S. Senator John McCain was just diagnosed with — and prolong survival in mice with the disease.

Satish Srinivas Kitambi, the paper’s first author, who is also based at the Karolinska Institutet, said the results got the team “really excited:” Continue reading “We do not want to create false hope”: Authors retract Cell paper they can’t replicate

Drip, drip: UCLA investigation finds more image duplications

Image duplications and unsupported data continue to plague a network of cancer researchers that includes the former vice chancellor for research at the University of California, Los Angeles, James Economou.

On July 2, the editors at Cancer Research retracted a 2011 paper that Economou published as last author, saying it suffered from image duplication and unsupported figures. This is the second retraction we’re aware of to come out of an investigation by UCLA’s Office of Research Policy and Compliance that has touched this group of scientists.

Here’s the notice for “Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction,” which says the retraction comes at the request of UCLA: Continue reading Drip, drip: UCLA investigation finds more image duplications

Science journal flags cancer paper under investigation for image manipulation

Science Signaling has issued an expression of concern for a 2016 paper, citing an institutional investigation into image manipulation.

According to a spokesperson for the journal, the corresponding author, Tanya Kalin, became concerned that two images in the paper had been manipulated. Kalin then notified the research integrity officer at Cincinnati Children’s Hospital Medical Center, where she is based.

On May 9 2017, Kalin alerted the journal to the investigation. A week later, the hospital’s research integrity officer followed up with the journal, flagging the figures under question. The journal then prepared an expression of concern (EOC) to alert readers to the issues and the institution’s investigation.

Here’s the EOC notice for “The transcription factor FOXF1 promotes prostate cancer by stimulating the mitogen-activated protein kinase ERK5:” Continue reading Science journal flags cancer paper under investigation for image manipulation

Diabetes researcher who sued to prevent retractions now has 13

A diabetes researcher who sued a publisher to protect several papers from being retracted recently received his 13th, in a prestigious gastroenterology journal.

Mario Saad, based at the University of Campinas in São Paulo, Brazil, has had a string of retractions over the past few years, including four in Diabetes after he lost a legal battle with the American Diabetes Association.

The latest retraction appears in Gastroenterology, citing possible image duplication. Saad is second-to-last author on the 2012 paper.

According to the retraction notice, the journal investigated data in several figures, and believes some were duplicated. The authors explained that the duplications resulted from inadvertently using wrong blots; still, the editors chose to retract the paper after determining they no longer had confidence in its conclusions.

Here’s the retraction notice for “Obesity-Induced Increase in Tumor Necrosis Factor-α Leads to Development of Colon Cancer in Mice:” Continue reading Diabetes researcher who sued to prevent retractions now has 13

Cancer paper retracted after author discovers signs of data manipulation

A molecular biology journal has retracted a 2017 cancer paper only two months after it appeared online, after the corresponding author notified the journal about possible data manipulation.

According to the notice, Chunsun Fan, from Qidong Liver Cancer Institute & Qidong People’s Hospital in China, requested the retraction after finding “signs of data manipulation” in the paper that was published online in April. The journal, FEBS Letters, acted quickly, publishing a retraction earlier this month.

Here’s the retraction notice for “MiR-19 regulates breast cancer cell aggressiveness by targeting profilin 1:” Continue reading Cancer paper retracted after author discovers signs of data manipulation

Springer purge of fake reviews takes down 10+ more neuroscience papers

Back in April, Springer retracted a record number 107 papers from Tumor Biology after uncovering evidence they were subject to fake peer reviews. But it appears that the Tumor Biology sweep was only part of the story.

During the Tumor Biology investigation, Springer found evidence that the “peer review process was compromised” in a dozen papers on brain cancer published in another journal. The 12 Molecular Neurobiology retractions have trickled in over the past year or so, published before and after the Tumor Biology sweep.

A spokesperson at Springer confirmed that the 12 retracted papers in Molecular Neurobiology were related to the Tumor Biology retractions for fake peer review: Continue reading Springer purge of fake reviews takes down 10+ more neuroscience papers

OSU researcher under investigation corrects paper cited 500 times

An EMBO journal has issued a correction for a well-cited 2012 review co-authored by a cancer researcher under investigation.

Carlo Croce, the last author on the review, has been beleaguered by misconduct accusations that have followed him for years (recently described in a lengthy article in the New York Times), and his university has recently re-opened an investigation into his work.

By our count, Croce — based at The Ohio State University — has logged six retractions, along with multiple expressions of concerns and corrections. The latest correction, in EMBO Molecular Medicine, notes the review lifted passages from multiple publications — and was in turn reused in later papers, as well.

Here’s the notice:

Continue reading OSU researcher under investigation corrects paper cited 500 times